Van ECK Associates Corp Increases Position in Urogen Pharma Ltd (URGN)

Share on StockTwits

Van ECK Associates Corp boosted its position in Urogen Pharma Ltd (NASDAQ:URGN) by 27.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 4,364 shares of the company’s stock after acquiring an additional 944 shares during the period. Van ECK Associates Corp’s holdings in Urogen Pharma were worth $188,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new stake in Urogen Pharma in the 3rd quarter valued at about $320,000. Mackenzie Financial Corp purchased a new position in Urogen Pharma during the 3rd quarter valued at about $347,000. Russell Investments Group Ltd. purchased a new position in Urogen Pharma during the 3rd quarter valued at about $119,000. Credit Suisse AG grew its holdings in Urogen Pharma by 53.1% during the 3rd quarter. Credit Suisse AG now owns 419,828 shares of the company’s stock valued at $19,828,000 after buying an additional 145,627 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in Urogen Pharma during the 4th quarter valued at about $418,000. Institutional investors and hedge funds own 75.46% of the company’s stock.

In other news, insider Mark Schoenberg sold 1,991 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $37.30, for a total transaction of $74,264.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

URGN stock opened at $38.06 on Friday. Urogen Pharma Ltd has a twelve month low of $34.61 and a twelve month high of $69.57. The stock has a market cap of $523.36 million, a price-to-earnings ratio of -7.93 and a beta of 1.48.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Thursday, February 28th. The company reported ($1.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.24) by ($0.22). Urogen Pharma had a negative return on equity of 70.67% and a negative net margin of 4,296.08%. As a group, equities research analysts expect that Urogen Pharma Ltd will post -5.47 earnings per share for the current fiscal year.

URGN has been the subject of a number of recent analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $63.00 target price on shares of Urogen Pharma in a report on Tuesday, March 5th. HC Wainwright initiated coverage on Urogen Pharma in a report on Tuesday, January 29th. They set a “buy” rating and a $82.00 target price for the company. Raymond James set a $57.00 target price on Urogen Pharma and gave the company a “buy” rating in a report on Friday, March 1st. Oppenheimer set a $70.00 target price on Urogen Pharma and gave the company a “buy” rating in a report on Thursday, February 28th. Finally, Zacks Investment Research raised Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 17th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $68.40.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Equities Focus and is the sole property of of Equities Focus. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.equitiesfocus.com/2019/03/17/van-eck-associates-corp-increases-position-in-urogen-pharma-ltd-urgn.html.

About Urogen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Featured Article: How can you know how many shares are floating?

Institutional Ownership by Quarter for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.